Susan Claire Hudson, Chief Legal Officer of Flowserve Corp, filed a Form 4 on November 2, 2026, reporting the acquisition of 31 shares of common stock under the company's Employee Stock Purchase Plan.
Hesham Mohamed Fakhry Mahmoud ElGabry, Chief Commercial Officer of Jumia Technologies AG, filed an amended initial statement of beneficial ownership on November 2, 2026, correcting a clerical error in the Power of Attorney exhibit and footnotes from the original filing dated October 29, 2026.
An amended initial beneficial ownership statement for Pedro Antonio Oliveira Fangueiro, Chief Technology Officer of Jumia Technologies AG, was filed with the SEC on November 2, 2026, correcting a clerical error in the Power of Attorney and footnotes from the original filing dated October …
An initial statement of beneficial ownership was filed on November 2, 2026, reporting William E. Waltz Jr. as a newly appointed director of Astec Industries Inc, with a triggering event date of October 29, 2026.
Saba Capital Management, L.P. filed a Form 4 on November 2, 2026, disclosing two open-market purchases of common stock in Japan Smaller Capitalization Fund Inc (NYSE:JOF) on October 29 and October 30, 2026.
The R. Randall Rollins Voting Trust U/A dated August 25, 1994 filed a Form 4 with the SEC on November 2, 2026, disclosing a purchase of Rollins, Inc. common stock on October 29, 2026.
James Budge, Chief Financial Officer of Hinge Health, Inc., filed a Form 4 on November 2, 2026, reporting a share-withholding transaction dated November 1, 2026, in which 4,614 shares of Class A Common Stock were relinquished to cover tax obligations from vesting restricted stock …
LOR Inc, a 10% owner of Rollins Inc, filed a Form 4 on November 2, 2026, reporting the purchase of 1,444,402 shares of Rollins common stock on October 29, 2026, at a weighted average price of $34.5864 per share.
Director Brian LeComte filed a Form 4 with the SEC on November 2, 2026, disclosing a purchase of 100 shares of Narragansett Bancorp, Inc. common stock on that same date.
Lawrence Otto Klein, Chief Executive Officer and Director of Oruka Therapeutics, Inc., filed a Form 4 on November 2, 2026, disclosing the exercise of an employee warrant and the sale of 25,000 shares of common stock on that same date pursuant to a Rule …